TransCode Therapeutics, a clinical-stage oncology company, has reported promising initial results from its Phase 1a trial of RNA-based cancer therapeutic TTX-MC138, demonstrating potential progress in treating metastatic tumors that overexpress microRNA-10b.
The company announced that 15 patients have been dosed across four dose levels, with the Safety Review Committee approving expanded enrollment. Ten patients remain active in the study, with the longest-treated patient showing stable disease after seven treatment cycles.
Early pharmacokinetic and pharmacodynamic data suggest successful target engagement, supporting the potential advancement to the Phase 1b dose expansion stage. The trial’s preliminary findings indicate no significant toxicities or disease progression to date, which could represent a critical milestone in developing innovative RNA therapeutics.
TTX-MC138 targets metastatic tumors through TransCode’s proprietary TTX nanoparticle platform, focusing on a unique biomarker of metastasis. This approach represents a novel strategy in addressing the complex challenges of treating advanced cancer.
The ongoing trial underscores TransCode’s commitment to developing intelligent RNA therapeutic solutions that could potentially transform treatment options for patients with metastatic diseases. By targeting specific microRNA expressions, the company aims to unlock new therapeutic approaches that may offer more precise and effective cancer interventions.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is TransCode Therapeutics Advances RNA Cancer Therapy with Promising Phase 1a Trial Results.